Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is developing a hearing loss drug that taps into the body’s regenerative capabilities. As the company prepares to advance the experimental treatment to mid-stage studies, it is planning an IPO to finance the research.
Frequency set a preliminary $100 million IPO target, according to paperwork filed with securities regulators on Friday. The Woburn, MA, company has applied for a Nasdaq listing under the stock symbol “FREQ.”
The process of hearing involves tiny hair cells that turn vibrations into electric signals picked up… Read more »
UNDERWRITERS AND PARTNERS
